Scientists identify molecular switch linking amino acids to cancer-relevant cell growth

Inside every cell lives a decision-making system. When amino acids—the raw materials for building proteins—become plentiful in the surrounding environment, cells receive a signal to grow. They ramp up protein synthesis, accelerate their metabolism, and begin to divide. But what exactly triggers this switch? Researchers at KAIST and Yonsei University have now mapped the molecular machinery that translates nutrient availability into growth, a discovery that could reshape how scientists approach cancer treatment.

The central player in this system is a protein complex called mTORC1, which functions as the cell's master growth regulator. When nutrients are abundant and energy is high, mTORC1 activates—telling the cell to grow, synthesize proteins, and metabolize fuel. This is normal and necessary. But in cancer cells, mTORC1 becomes hyperactive, driving uncontrolled proliferation. For decades, cancer researchers have viewed mTORC1 as an obvious target for drugs. Yet directly blocking it has proven problematic: mTORC1 is also essential for healthy cells, so inhibiting it damages normal tissue alongside tumor cells.

The breakthrough came from studying a large protein assembly called the multi-tRNA synthetase complex, or MSC. This structure houses multiple enzymes whose primary job is helping build proteins—they attach specific amino acids to transfer RNA molecules, a fundamental step in translation. But the KAIST and Yonsei team discovered that the MSC does something else entirely. It acts as a control center that monitors nutrient signals and, when conditions are right, releases a protein called LARS1 to activate mTORC1.

LARS1 itself is a dual-function protein. It performs its traditional role as an enzyme that attaches leucine—a crucial amino acid—to its corresponding transfer RNA. But it also serves as an internal leucine sensor, detecting when amino acids are abundant. When nutrient signals arrive, LARS1 undergoes a chemical modification called phosphorylation, in which a small molecular tag attaches to the protein and changes how it behaves. This phosphorylation causes LARS1 to break free from IARS1, another protein that normally anchors it to the MSC. Once released, LARS1 travels through the cell and activates mTORC1. When nutrients are scarce, LARS1 remains tethered to the MSC, and the growth signal stays silent.

To understand the structural basis of this mechanism, the researchers used cryo-electron microscopy, a technique that freezes protein complexes at near-absolute-zero temperatures and images them at near-atomic resolution. The images revealed how tightly LARS1 and IARS1 normally bind to each other, and how phosphorylation weakens that grip. The team also created engineered versions of LARS1 designed to mimic the phosphorylated state, and found that these mutant proteins substantially boosted mTORC1 activity, confirming that phosphorylation is indeed the molecular switch.

The significance of this work extends beyond basic science. Current anticancer drugs that directly inhibit mTORC1 are effective at slowing tumor growth, but they also suppress normal cellular functions in healthy tissue, limiting their therapeutic window. The KAIST and Yonsei findings suggest a different approach: instead of blocking mTORC1 itself, researchers could target the kinase enzyme responsible for phosphorylating LARS1. By intercepting the growth signal further upstream—at the point where amino acid availability is first translated into a chemical command—a drug could shut down cancer cell growth while leaving the mTORC1 pathway intact in normal cells. The next phase of research will focus on identifying that kinase and understanding how it is regulated, work that could eventually lead to a new generation of anticancer therapies with fewer side effects.